nodes	percent_of_prediction	percent_of_DWPC	metapath
Mefloquine—ABCB1—hematologic cancer	0.0926	1	CbGaD
Mefloquine—ACHE—Irinotecan—hematologic cancer	0.034	0.0689	CbGbCtD
Mefloquine—CYP19A1—Betamethasone—hematologic cancer	0.0278	0.0564	CbGbCtD
Mefloquine—BCHE—Triamcinolone—hematologic cancer	0.027	0.0547	CbGbCtD
Mefloquine—BCHE—Irinotecan—hematologic cancer	0.0205	0.0415	CbGbCtD
Mefloquine—ABCB1—Lenalidomide—hematologic cancer	0.0185	0.0375	CbGbCtD
Mefloquine—BCHE—Cisplatin—hematologic cancer	0.0167	0.0338	CbGbCtD
Mefloquine—CYP2D6—Lomustine—hematologic cancer	0.0162	0.0329	CbGbCtD
Mefloquine—CYP19A1—Dexamethasone—hematologic cancer	0.0162	0.0328	CbGbCtD
Mefloquine—CYP2D6—Idarubicin—hematologic cancer	0.0144	0.0293	CbGbCtD
Mefloquine—CYP2D6—Hydroxyurea—hematologic cancer	0.0123	0.0249	CbGbCtD
Mefloquine—CYP3A4—Bexarotene—hematologic cancer	0.0111	0.0225	CbGbCtD
Mefloquine—ABCB1—Daunorubicin—hematologic cancer	0.0108	0.022	CbGbCtD
Mefloquine—CYP2D6—Bortezomib—hematologic cancer	0.0107	0.0217	CbGbCtD
Mefloquine—ABCB1—Alitretinoin—hematologic cancer	0.0106	0.0216	CbGbCtD
Mefloquine—CYP3A4—Lomustine—hematologic cancer	0.0103	0.0209	CbGbCtD
Mefloquine—CYP3A4—Busulfan—hematologic cancer	0.0103	0.0209	CbGbCtD
Mefloquine—CYP19A1—ovarian follicle—hematologic cancer	0.0103	0.153	CbGeAlD
Mefloquine—CYP3A4—Thiotepa—hematologic cancer	0.00919	0.0186	CbGbCtD
Mefloquine—ABCB1—Imatinib—hematologic cancer	0.00831	0.0169	CbGbCtD
Mefloquine—CYP2D6—Imatinib—hematologic cancer	0.00783	0.0159	CbGbCtD
Mefloquine—ABCB1—Nilotinib—hematologic cancer	0.00755	0.0153	CbGbCtD
Mefloquine—ABCB1—Vinorelbine—hematologic cancer	0.00749	0.0152	CbGbCtD
Mefloquine—CYP3A4—Methoxsalen—hematologic cancer	0.00714	0.0145	CbGbCtD
Mefloquine—CYP2D6—Nilotinib—hematologic cancer	0.00712	0.0144	CbGbCtD
Mefloquine—CYP2D6—Vinorelbine—hematologic cancer	0.00706	0.0143	CbGbCtD
Mefloquine—CYP3A4—Bortezomib—hematologic cancer	0.0068	0.0138	CbGbCtD
Mefloquine—ABCB1—Dasatinib—hematologic cancer	0.00667	0.0135	CbGbCtD
Mefloquine—ABCB1—Mitoxantrone—hematologic cancer	0.00659	0.0134	CbGbCtD
Mefloquine—CYP3A4—Daunorubicin—hematologic cancer	0.0065	0.0132	CbGbCtD
Mefloquine—ABCB1—Betamethasone—hematologic cancer	0.00588	0.0119	CbGbCtD
Mefloquine—ABCB1—Gemcitabine—hematologic cancer	0.00582	0.0118	CbGbCtD
Mefloquine—ABCB1—Prednisolone—hematologic cancer	0.0058	0.0118	CbGbCtD
Mefloquine—CYP3A4—Cytarabine—hematologic cancer	0.00573	0.0116	CbGbCtD
Mefloquine—CYP3A4—Teniposide—hematologic cancer	0.00565	0.0115	CbGbCtD
Mefloquine—ABCB1—Prednisone—hematologic cancer	0.00548	0.0111	CbGbCtD
Mefloquine—CYP3A4—Ifosfamide—hematologic cancer	0.00521	0.0106	CbGbCtD
Mefloquine—ABCB1—Irinotecan—hematologic cancer	0.00519	0.0105	CbGbCtD
Mefloquine—CYP3A4—Imatinib—hematologic cancer	0.00498	0.0101	CbGbCtD
Mefloquine—CYP3A4—Ruxolitinib—hematologic cancer	0.00469	0.00951	CbGbCtD
Mefloquine—ABCB1—Vinblastine—hematologic cancer	0.00461	0.00936	CbGbCtD
Mefloquine—ABCB1—Vincristine—hematologic cancer	0.00454	0.0092	CbGbCtD
Mefloquine—CYP3A4—Nilotinib—hematologic cancer	0.00452	0.00918	CbGbCtD
Mefloquine—CYP3A4—Vinorelbine—hematologic cancer	0.00449	0.0091	CbGbCtD
Mefloquine—HBA1—hematopoietic system—hematologic cancer	0.00442	0.0658	CbGeAlD
Mefloquine—CYP2D6—Vinblastine—hematologic cancer	0.00435	0.00882	CbGbCtD
Mefloquine—ABCB1—Cisplatin—hematologic cancer	0.00423	0.00858	CbGbCtD
Mefloquine—ABCB1—Etoposide—hematologic cancer	0.00416	0.00843	CbGbCtD
Mefloquine—CYP3A4—Triamcinolone—hematologic cancer	0.0041	0.00832	CbGbCtD
Mefloquine—HBA2—hematopoietic system—hematologic cancer	0.00406	0.0604	CbGeAlD
Mefloquine—CYP3A4—Dasatinib—hematologic cancer	0.004	0.00811	CbGbCtD
Mefloquine—CYP3A4—Mitoxantrone—hematologic cancer	0.00395	0.00801	CbGbCtD
Mefloquine—CYP3A4—Betamethasone—hematologic cancer	0.00352	0.00714	CbGbCtD
Mefloquine—CYP3A4—Prednisolone—hematologic cancer	0.00347	0.00705	CbGbCtD
Mefloquine—ABCB1—Dexamethasone—hematologic cancer	0.00342	0.00693	CbGbCtD
Mefloquine—CYP3A4—Prednisone—hematologic cancer	0.00328	0.00665	CbGbCtD
Mefloquine—CYP2D6—Dexamethasone—hematologic cancer	0.00322	0.00653	CbGbCtD
Mefloquine—CYP3A4—Irinotecan—hematologic cancer	0.00311	0.00631	CbGbCtD
Mefloquine—HBA1—blood—hematologic cancer	0.00293	0.0436	CbGeAlD
Mefloquine—ABCB1—Doxorubicin—hematologic cancer	0.00284	0.00575	CbGbCtD
Mefloquine—HBA1—bone marrow—hematologic cancer	0.00284	0.0422	CbGeAlD
Mefloquine—CYP3A4—Vinblastine—hematologic cancer	0.00276	0.00561	CbGbCtD
Mefloquine—ABCB1—Methotrexate—hematologic cancer	0.00275	0.00557	CbGbCtD
Mefloquine—CYP3A4—Vincristine—hematologic cancer	0.00272	0.00551	CbGbCtD
Mefloquine—HBA2—blood—hematologic cancer	0.00269	0.04	CbGeAlD
Mefloquine—CYP2D6—Doxorubicin—hematologic cancer	0.00267	0.00542	CbGbCtD
Mefloquine—HBA2—bone marrow—hematologic cancer	0.0026	0.0387	CbGeAlD
Mefloquine—HBA1—lung—hematologic cancer	0.00257	0.0382	CbGeAlD
Mefloquine—CYP3A4—Etoposide—hematologic cancer	0.00249	0.00505	CbGbCtD
Mefloquine—HBA1—testis—hematologic cancer	0.00242	0.0361	CbGeAlD
Mefloquine—HBA2—lung—hematologic cancer	0.00236	0.0351	CbGeAlD
Mefloquine—HBA2—testis—hematologic cancer	0.00223	0.0331	CbGeAlD
Mefloquine—ADORA2A—hematopoietic system—hematologic cancer	0.00211	0.0315	CbGeAlD
Mefloquine—CYP3A4—Dexamethasone—hematologic cancer	0.00205	0.00415	CbGbCtD
Mefloquine—ADORA1—hematopoietic system—hematologic cancer	0.00182	0.0272	CbGeAlD
Mefloquine—HBA1—lymph node—hematologic cancer	0.00176	0.0262	CbGeAlD
Mefloquine—CYP3A4—Doxorubicin—hematologic cancer	0.0017	0.00345	CbGbCtD
Mefloquine—HBA2—lymph node—hematologic cancer	0.00161	0.024	CbGeAlD
Mefloquine—ADORA2A—gonad—hematologic cancer	0.00161	0.0239	CbGeAlD
Mefloquine—ADORA2A—blood—hematologic cancer	0.0014	0.0208	CbGeAlD
Mefloquine—CYP19A1—hematopoietic system—hematologic cancer	0.00124	0.0184	CbGeAlD
Mefloquine—ADORA2A—testis—hematologic cancer	0.00116	0.0172	CbGeAlD
Mefloquine—ADORA1—lung—hematologic cancer	0.00106	0.0158	CbGeAlD
Mefloquine—ADORA1—testis—hematologic cancer	0.001	0.0149	CbGeAlD
Mefloquine—ACHE—testis—hematologic cancer	0.000994	0.0148	CbGeAlD
Mefloquine—CYP19A1—gonad—hematologic cancer	0.000941	0.014	CbGeAlD
Mefloquine—BCHE—hematopoietic system—hematologic cancer	0.000891	0.0133	CbGeAlD
Mefloquine—CYP19A1—blood—hematologic cancer	0.00082	0.0122	CbGeAlD
Mefloquine—ADORA1—lymph node—hematologic cancer	0.000725	0.0108	CbGeAlD
Mefloquine—ACHE—lymph node—hematologic cancer	0.00072	0.0107	CbGeAlD
Mefloquine—CYP19A1—testis—hematologic cancer	0.000678	0.0101	CbGeAlD
Mefloquine—CYP3A4—hematopoietic system—hematologic cancer	0.0006	0.00893	CbGeAlD
Mefloquine—CYP2D6—hematopoietic system—hematologic cancer	0.000591	0.00879	CbGeAlD
Mefloquine—BCHE—blood—hematologic cancer	0.000591	0.00879	CbGeAlD
Mefloquine—BCHE—bone marrow—hematologic cancer	0.000571	0.00851	CbGeAlD
Mefloquine—BCHE—lung—hematologic cancer	0.000518	0.00771	CbGeAlD
Mefloquine—CYP19A1—lymph node—hematologic cancer	0.000492	0.00732	CbGeAlD
Mefloquine—BCHE—testis—hematologic cancer	0.000488	0.00727	CbGeAlD
Mefloquine—ABCB1—hematopoietic system—hematologic cancer	0.000425	0.00632	CbGeAlD
Mefloquine—CYP3A4—blood—hematologic cancer	0.000398	0.00592	CbGeAlD
Mefloquine—CYP2D6—blood—hematologic cancer	0.000391	0.00582	CbGeAlD
Mefloquine—BCHE—lymph node—hematologic cancer	0.000354	0.00527	CbGeAlD
Mefloquine—CYP2D6—testis—hematologic cancer	0.000324	0.00482	CbGeAlD
Mefloquine—ABCB1—gonad—hematologic cancer	0.000323	0.00481	CbGeAlD
Mefloquine—ABCB1—blood—hematologic cancer	0.000281	0.00419	CbGeAlD
Mefloquine—ABCB1—bone marrow—hematologic cancer	0.000272	0.00405	CbGeAlD
Mefloquine—ABCB1—lung—hematologic cancer	0.000247	0.00367	CbGeAlD
Mefloquine—ABCB1—testis—hematologic cancer	0.000233	0.00347	CbGeAlD
Mefloquine—ABCB1—lymph node—hematologic cancer	0.000169	0.00251	CbGeAlD
Mefloquine—Mediastinal disorder—Epirubicin—hematologic cancer	2.79e-05	0.000119	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Dexamethasone—hematologic cancer	2.79e-05	0.000119	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Betamethasone—hematologic cancer	2.79e-05	0.000119	CcSEcCtD
Mefloquine—Fatigue—Betamethasone—hematologic cancer	2.78e-05	0.000119	CcSEcCtD
Mefloquine—Fatigue—Dexamethasone—hematologic cancer	2.78e-05	0.000119	CcSEcCtD
Mefloquine—Chills—Epirubicin—hematologic cancer	2.78e-05	0.000119	CcSEcCtD
Mefloquine—Pruritus—Etoposide—hematologic cancer	2.78e-05	0.000118	CcSEcCtD
Mefloquine—Shock—Prednisone—hematologic cancer	2.77e-05	0.000118	CcSEcCtD
Mefloquine—Visual impairment—Doxorubicin—hematologic cancer	2.76e-05	0.000118	CcSEcCtD
Mefloquine—Nervous system disorder—Prednisone—hematologic cancer	2.76e-05	0.000118	CcSEcCtD
Mefloquine—Tachycardia—Prednisone—hematologic cancer	2.74e-05	0.000117	CcSEcCtD
Mefloquine—Alopecia—Epirubicin—hematologic cancer	2.73e-05	0.000117	CcSEcCtD
Mefloquine—Skin disorder—Prednisone—hematologic cancer	2.73e-05	0.000117	CcSEcCtD
Mefloquine—Nausea—Gemcitabine—hematologic cancer	2.73e-05	0.000117	CcSEcCtD
Mefloquine—Vomiting—Cisplatin—hematologic cancer	2.72e-05	0.000116	CcSEcCtD
Mefloquine—Hyperhidrosis—Prednisone—hematologic cancer	2.72e-05	0.000116	CcSEcCtD
Mefloquine—Vision blurred—Methotrexate—hematologic cancer	2.71e-05	0.000116	CcSEcCtD
Mefloquine—Mental disorder—Epirubicin—hematologic cancer	2.71e-05	0.000116	CcSEcCtD
Mefloquine—Erythema multiforme—Doxorubicin—hematologic cancer	2.71e-05	0.000116	CcSEcCtD
Mefloquine—Rash—Cisplatin—hematologic cancer	2.7e-05	0.000115	CcSEcCtD
Mefloquine—Dermatitis—Cisplatin—hematologic cancer	2.7e-05	0.000115	CcSEcCtD
Mefloquine—Erythema—Epirubicin—hematologic cancer	2.69e-05	0.000115	CcSEcCtD
Mefloquine—Malnutrition—Epirubicin—hematologic cancer	2.69e-05	0.000115	CcSEcCtD
Mefloquine—Diarrhoea—Etoposide—hematologic cancer	2.68e-05	0.000115	CcSEcCtD
Mefloquine—Eye disorder—Doxorubicin—hematologic cancer	2.68e-05	0.000114	CcSEcCtD
Mefloquine—Ill-defined disorder—Methotrexate—hematologic cancer	2.67e-05	0.000114	CcSEcCtD
Mefloquine—Tinnitus—Doxorubicin—hematologic cancer	2.67e-05	0.000114	CcSEcCtD
Mefloquine—Feeling abnormal—Dexamethasone—hematologic cancer	2.66e-05	0.000114	CcSEcCtD
Mefloquine—Feeling abnormal—Betamethasone—hematologic cancer	2.66e-05	0.000114	CcSEcCtD
Mefloquine—Cardiac disorder—Doxorubicin—hematologic cancer	2.66e-05	0.000113	CcSEcCtD
Mefloquine—Flushing—Doxorubicin—hematologic cancer	2.66e-05	0.000113	CcSEcCtD
Mefloquine—Gastrointestinal pain—Betamethasone—hematologic cancer	2.64e-05	0.000113	CcSEcCtD
Mefloquine—Gastrointestinal pain—Dexamethasone—hematologic cancer	2.64e-05	0.000113	CcSEcCtD
Mefloquine—Hypersensitivity—Triamcinolone—hematologic cancer	2.62e-05	0.000112	CcSEcCtD
Mefloquine—Angiopathy—Doxorubicin—hematologic cancer	2.6e-05	0.000111	CcSEcCtD
Mefloquine—Malaise—Methotrexate—hematologic cancer	2.6e-05	0.000111	CcSEcCtD
Mefloquine—Dizziness—Etoposide—hematologic cancer	2.59e-05	0.000111	CcSEcCtD
Mefloquine—Muscle spasms—Epirubicin—hematologic cancer	2.59e-05	0.000111	CcSEcCtD
Mefloquine—Vertigo—Methotrexate—hematologic cancer	2.59e-05	0.00011	CcSEcCtD
Mefloquine—Mediastinal disorder—Doxorubicin—hematologic cancer	2.58e-05	0.00011	CcSEcCtD
Mefloquine—Leukopenia—Methotrexate—hematologic cancer	2.58e-05	0.00011	CcSEcCtD
Mefloquine—Chills—Doxorubicin—hematologic cancer	2.57e-05	0.00011	CcSEcCtD
Mefloquine—Urticaria—Betamethasone—hematologic cancer	2.56e-05	0.00011	CcSEcCtD
Mefloquine—Urticaria—Dexamethasone—hematologic cancer	2.56e-05	0.00011	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Prednisone—hematologic cancer	2.56e-05	0.000109	CcSEcCtD
Mefloquine—Dizziness—Prednisolone—hematologic cancer	2.56e-05	0.000109	CcSEcCtD
Mefloquine—Asthenia—Triamcinolone—hematologic cancer	2.55e-05	0.000109	CcSEcCtD
Mefloquine—Abdominal pain—Dexamethasone—hematologic cancer	2.55e-05	0.000109	CcSEcCtD
Mefloquine—Abdominal pain—Betamethasone—hematologic cancer	2.55e-05	0.000109	CcSEcCtD
Mefloquine—Body temperature increased—Betamethasone—hematologic cancer	2.55e-05	0.000109	CcSEcCtD
Mefloquine—Body temperature increased—Dexamethasone—hematologic cancer	2.55e-05	0.000109	CcSEcCtD
Mefloquine—Nausea—Cisplatin—hematologic cancer	2.54e-05	0.000109	CcSEcCtD
Mefloquine—Insomnia—Prednisone—hematologic cancer	2.54e-05	0.000109	CcSEcCtD
Mefloquine—Vision blurred—Epirubicin—hematologic cancer	2.54e-05	0.000108	CcSEcCtD
Mefloquine—Alopecia—Doxorubicin—hematologic cancer	2.53e-05	0.000108	CcSEcCtD
Mefloquine—Paraesthesia—Prednisone—hematologic cancer	2.52e-05	0.000108	CcSEcCtD
Mefloquine—Pruritus—Triamcinolone—hematologic cancer	2.52e-05	0.000107	CcSEcCtD
Mefloquine—Mental disorder—Doxorubicin—hematologic cancer	2.51e-05	0.000107	CcSEcCtD
Mefloquine—Ill-defined disorder—Epirubicin—hematologic cancer	2.5e-05	0.000107	CcSEcCtD
Mefloquine—Convulsion—Methotrexate—hematologic cancer	2.49e-05	0.000107	CcSEcCtD
Mefloquine—Vomiting—Etoposide—hematologic cancer	2.49e-05	0.000106	CcSEcCtD
Mefloquine—Erythema—Doxorubicin—hematologic cancer	2.49e-05	0.000106	CcSEcCtD
Mefloquine—Malnutrition—Doxorubicin—hematologic cancer	2.49e-05	0.000106	CcSEcCtD
Mefloquine—Agitation—Epirubicin—hematologic cancer	2.48e-05	0.000106	CcSEcCtD
Mefloquine—Dyspepsia—Prednisone—hematologic cancer	2.47e-05	0.000106	CcSEcCtD
Mefloquine—Rash—Etoposide—hematologic cancer	2.47e-05	0.000106	CcSEcCtD
Mefloquine—Dermatitis—Etoposide—hematologic cancer	2.47e-05	0.000106	CcSEcCtD
Mefloquine—Headache—Etoposide—hematologic cancer	2.46e-05	0.000105	CcSEcCtD
Mefloquine—Myalgia—Methotrexate—hematologic cancer	2.45e-05	0.000105	CcSEcCtD
Mefloquine—Arthralgia—Methotrexate—hematologic cancer	2.45e-05	0.000105	CcSEcCtD
Mefloquine—Chest pain—Methotrexate—hematologic cancer	2.45e-05	0.000105	CcSEcCtD
Mefloquine—Decreased appetite—Prednisone—hematologic cancer	2.44e-05	0.000104	CcSEcCtD
Mefloquine—Rash—Prednisolone—hematologic cancer	2.44e-05	0.000104	CcSEcCtD
Mefloquine—Dermatitis—Prednisolone—hematologic cancer	2.44e-05	0.000104	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	2.43e-05	0.000104	CcSEcCtD
Mefloquine—Malaise—Epirubicin—hematologic cancer	2.43e-05	0.000104	CcSEcCtD
Mefloquine—Fatigue—Prednisone—hematologic cancer	2.42e-05	0.000103	CcSEcCtD
Mefloquine—Headache—Prednisolone—hematologic cancer	2.42e-05	0.000103	CcSEcCtD
Mefloquine—Discomfort—Methotrexate—hematologic cancer	2.42e-05	0.000103	CcSEcCtD
Mefloquine—Vertigo—Epirubicin—hematologic cancer	2.42e-05	0.000103	CcSEcCtD
Mefloquine—Syncope—Epirubicin—hematologic cancer	2.42e-05	0.000103	CcSEcCtD
Mefloquine—Leukopenia—Epirubicin—hematologic cancer	2.41e-05	0.000103	CcSEcCtD
Mefloquine—Muscle spasms—Doxorubicin—hematologic cancer	2.4e-05	0.000102	CcSEcCtD
Mefloquine—Palpitations—Epirubicin—hematologic cancer	2.38e-05	0.000102	CcSEcCtD
Mefloquine—Confusional state—Methotrexate—hematologic cancer	2.37e-05	0.000101	CcSEcCtD
Mefloquine—Loss of consciousness—Epirubicin—hematologic cancer	2.37e-05	0.000101	CcSEcCtD
Mefloquine—Dizziness—Triamcinolone—hematologic cancer	2.35e-05	0.0001	CcSEcCtD
Mefloquine—Anaphylactic shock—Methotrexate—hematologic cancer	2.35e-05	0.0001	CcSEcCtD
Mefloquine—Vision blurred—Doxorubicin—hematologic cancer	2.35e-05	0.0001	CcSEcCtD
Mefloquine—Convulsion—Epirubicin—hematologic cancer	2.33e-05	9.97e-05	CcSEcCtD
Mefloquine—Nausea—Etoposide—hematologic cancer	2.33e-05	9.95e-05	CcSEcCtD
Mefloquine—Hypertension—Epirubicin—hematologic cancer	2.33e-05	9.93e-05	CcSEcCtD
Mefloquine—Feeling abnormal—Prednisone—hematologic cancer	2.32e-05	9.89e-05	CcSEcCtD
Mefloquine—Asthenia—Betamethasone—hematologic cancer	2.32e-05	9.89e-05	CcSEcCtD
Mefloquine—Asthenia—Dexamethasone—hematologic cancer	2.32e-05	9.89e-05	CcSEcCtD
Mefloquine—Ill-defined disorder—Doxorubicin—hematologic cancer	2.31e-05	9.88e-05	CcSEcCtD
Mefloquine—Nervous system disorder—Methotrexate—hematologic cancer	2.3e-05	9.84e-05	CcSEcCtD
Mefloquine—Thrombocytopenia—Methotrexate—hematologic cancer	2.3e-05	9.82e-05	CcSEcCtD
Mefloquine—Gastrointestinal pain—Prednisone—hematologic cancer	2.3e-05	9.82e-05	CcSEcCtD
Mefloquine—Nausea—Prednisolone—hematologic cancer	2.3e-05	9.81e-05	CcSEcCtD
Mefloquine—Chest pain—Epirubicin—hematologic cancer	2.29e-05	9.79e-05	CcSEcCtD
Mefloquine—Arthralgia—Epirubicin—hematologic cancer	2.29e-05	9.79e-05	CcSEcCtD
Mefloquine—Myalgia—Epirubicin—hematologic cancer	2.29e-05	9.79e-05	CcSEcCtD
Mefloquine—Agitation—Doxorubicin—hematologic cancer	2.29e-05	9.78e-05	CcSEcCtD
Mefloquine—Anxiety—Epirubicin—hematologic cancer	2.29e-05	9.76e-05	CcSEcCtD
Mefloquine—Pruritus—Dexamethasone—hematologic cancer	2.28e-05	9.75e-05	CcSEcCtD
Mefloquine—Pruritus—Betamethasone—hematologic cancer	2.28e-05	9.75e-05	CcSEcCtD
Mefloquine—Skin disorder—Methotrexate—hematologic cancer	2.28e-05	9.74e-05	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	2.28e-05	9.73e-05	CcSEcCtD
Mefloquine—Hyperhidrosis—Methotrexate—hematologic cancer	2.27e-05	9.7e-05	CcSEcCtD
Mefloquine—Discomfort—Epirubicin—hematologic cancer	2.27e-05	9.68e-05	CcSEcCtD
Mefloquine—Vomiting—Triamcinolone—hematologic cancer	2.26e-05	9.66e-05	CcSEcCtD
Mefloquine—Malaise—Doxorubicin—hematologic cancer	2.25e-05	9.6e-05	CcSEcCtD
Mefloquine—Rash—Triamcinolone—hematologic cancer	2.24e-05	9.58e-05	CcSEcCtD
Mefloquine—Dermatitis—Triamcinolone—hematologic cancer	2.24e-05	9.57e-05	CcSEcCtD
Mefloquine—Vertigo—Doxorubicin—hematologic cancer	2.24e-05	9.56e-05	CcSEcCtD
Mefloquine—Syncope—Doxorubicin—hematologic cancer	2.24e-05	9.55e-05	CcSEcCtD
Mefloquine—Urticaria—Prednisone—hematologic cancer	2.23e-05	9.54e-05	CcSEcCtD
Mefloquine—Leukopenia—Doxorubicin—hematologic cancer	2.23e-05	9.53e-05	CcSEcCtD
Mefloquine—Headache—Triamcinolone—hematologic cancer	2.23e-05	9.52e-05	CcSEcCtD
Mefloquine—Abdominal pain—Prednisone—hematologic cancer	2.22e-05	9.49e-05	CcSEcCtD
Mefloquine—Body temperature increased—Prednisone—hematologic cancer	2.22e-05	9.49e-05	CcSEcCtD
Mefloquine—Confusional state—Epirubicin—hematologic cancer	2.22e-05	9.47e-05	CcSEcCtD
Mefloquine—Diarrhoea—Betamethasone—hematologic cancer	2.21e-05	9.43e-05	CcSEcCtD
Mefloquine—Diarrhoea—Dexamethasone—hematologic cancer	2.21e-05	9.43e-05	CcSEcCtD
Mefloquine—Palpitations—Doxorubicin—hematologic cancer	2.2e-05	9.41e-05	CcSEcCtD
Mefloquine—Anaphylactic shock—Epirubicin—hematologic cancer	2.2e-05	9.39e-05	CcSEcCtD
Mefloquine—Oedema—Epirubicin—hematologic cancer	2.2e-05	9.39e-05	CcSEcCtD
Mefloquine—Hypotension—Methotrexate—hematologic cancer	2.2e-05	9.37e-05	CcSEcCtD
Mefloquine—Loss of consciousness—Doxorubicin—hematologic cancer	2.19e-05	9.36e-05	CcSEcCtD
Mefloquine—Shock—Epirubicin—hematologic cancer	2.16e-05	9.24e-05	CcSEcCtD
Mefloquine—Convulsion—Doxorubicin—hematologic cancer	2.16e-05	9.22e-05	CcSEcCtD
Mefloquine—Nervous system disorder—Epirubicin—hematologic cancer	2.16e-05	9.21e-05	CcSEcCtD
Mefloquine—Thrombocytopenia—Epirubicin—hematologic cancer	2.15e-05	9.19e-05	CcSEcCtD
Mefloquine—Hypertension—Doxorubicin—hematologic cancer	2.15e-05	9.19e-05	CcSEcCtD
Mefloquine—Tachycardia—Epirubicin—hematologic cancer	2.15e-05	9.16e-05	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	2.14e-05	9.14e-05	CcSEcCtD
Mefloquine—Skin disorder—Epirubicin—hematologic cancer	2.14e-05	9.12e-05	CcSEcCtD
Mefloquine—Dizziness—Dexamethasone—hematologic cancer	2.13e-05	9.11e-05	CcSEcCtD
Mefloquine—Dizziness—Betamethasone—hematologic cancer	2.13e-05	9.11e-05	CcSEcCtD
Mefloquine—Hyperhidrosis—Epirubicin—hematologic cancer	2.13e-05	9.08e-05	CcSEcCtD
Mefloquine—Insomnia—Methotrexate—hematologic cancer	2.13e-05	9.07e-05	CcSEcCtD
Mefloquine—Myalgia—Doxorubicin—hematologic cancer	2.12e-05	9.06e-05	CcSEcCtD
Mefloquine—Chest pain—Doxorubicin—hematologic cancer	2.12e-05	9.06e-05	CcSEcCtD
Mefloquine—Arthralgia—Doxorubicin—hematologic cancer	2.12e-05	9.06e-05	CcSEcCtD
Mefloquine—Anxiety—Doxorubicin—hematologic cancer	2.12e-05	9.03e-05	CcSEcCtD
Mefloquine—Nausea—Triamcinolone—hematologic cancer	2.11e-05	9.02e-05	CcSEcCtD
Mefloquine—Paraesthesia—Methotrexate—hematologic cancer	2.11e-05	9.01e-05	CcSEcCtD
Mefloquine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	2.11e-05	9e-05	CcSEcCtD
Mefloquine—Discomfort—Doxorubicin—hematologic cancer	2.1e-05	8.95e-05	CcSEcCtD
Mefloquine—Dyspnoea—Methotrexate—hematologic cancer	2.09e-05	8.94e-05	CcSEcCtD
Mefloquine—Somnolence—Methotrexate—hematologic cancer	2.09e-05	8.92e-05	CcSEcCtD
Mefloquine—Hypersensitivity—Prednisone—hematologic cancer	2.07e-05	8.84e-05	CcSEcCtD
Mefloquine—Dyspepsia—Methotrexate—hematologic cancer	2.07e-05	8.83e-05	CcSEcCtD
Mefloquine—Hypotension—Epirubicin—hematologic cancer	2.05e-05	8.77e-05	CcSEcCtD
Mefloquine—Vomiting—Dexamethasone—hematologic cancer	2.05e-05	8.76e-05	CcSEcCtD
Mefloquine—Vomiting—Betamethasone—hematologic cancer	2.05e-05	8.76e-05	CcSEcCtD
Mefloquine—Confusional state—Doxorubicin—hematologic cancer	2.05e-05	8.76e-05	CcSEcCtD
Mefloquine—Decreased appetite—Methotrexate—hematologic cancer	2.04e-05	8.72e-05	CcSEcCtD
Mefloquine—Rash—Dexamethasone—hematologic cancer	2.04e-05	8.69e-05	CcSEcCtD
Mefloquine—Rash—Betamethasone—hematologic cancer	2.04e-05	8.69e-05	CcSEcCtD
Mefloquine—Anaphylactic shock—Doxorubicin—hematologic cancer	2.03e-05	8.69e-05	CcSEcCtD
Mefloquine—Oedema—Doxorubicin—hematologic cancer	2.03e-05	8.69e-05	CcSEcCtD
Mefloquine—Dermatitis—Betamethasone—hematologic cancer	2.03e-05	8.68e-05	CcSEcCtD
Mefloquine—Dermatitis—Dexamethasone—hematologic cancer	2.03e-05	8.68e-05	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Methotrexate—hematologic cancer	2.03e-05	8.66e-05	CcSEcCtD
Mefloquine—Fatigue—Methotrexate—hematologic cancer	2.03e-05	8.65e-05	CcSEcCtD
Mefloquine—Headache—Betamethasone—hematologic cancer	2.02e-05	8.64e-05	CcSEcCtD
Mefloquine—Headache—Dexamethasone—hematologic cancer	2.02e-05	8.64e-05	CcSEcCtD
Mefloquine—Asthenia—Prednisone—hematologic cancer	2.02e-05	8.61e-05	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	2e-05	8.55e-05	CcSEcCtD
Mefloquine—Shock—Doxorubicin—hematologic cancer	2e-05	8.55e-05	CcSEcCtD
Mefloquine—Nervous system disorder—Doxorubicin—hematologic cancer	2e-05	8.52e-05	CcSEcCtD
Mefloquine—Thrombocytopenia—Doxorubicin—hematologic cancer	1.99e-05	8.51e-05	CcSEcCtD
Mefloquine—Pruritus—Prednisone—hematologic cancer	1.99e-05	8.49e-05	CcSEcCtD
Mefloquine—Insomnia—Epirubicin—hematologic cancer	1.99e-05	8.49e-05	CcSEcCtD
Mefloquine—Tachycardia—Doxorubicin—hematologic cancer	1.99e-05	8.48e-05	CcSEcCtD
Mefloquine—Skin disorder—Doxorubicin—hematologic cancer	1.98e-05	8.44e-05	CcSEcCtD
Mefloquine—Paraesthesia—Epirubicin—hematologic cancer	1.97e-05	8.43e-05	CcSEcCtD
Mefloquine—Hyperhidrosis—Doxorubicin—hematologic cancer	1.97e-05	8.4e-05	CcSEcCtD
Mefloquine—Dyspnoea—Epirubicin—hematologic cancer	1.96e-05	8.37e-05	CcSEcCtD
Mefloquine—Somnolence—Epirubicin—hematologic cancer	1.95e-05	8.35e-05	CcSEcCtD
Mefloquine—Feeling abnormal—Methotrexate—hematologic cancer	1.94e-05	8.27e-05	CcSEcCtD
Mefloquine—Dyspepsia—Epirubicin—hematologic cancer	1.94e-05	8.26e-05	CcSEcCtD
Mefloquine—Diarrhoea—Prednisone—hematologic cancer	1.92e-05	8.21e-05	CcSEcCtD
Mefloquine—Gastrointestinal pain—Methotrexate—hematologic cancer	1.92e-05	8.2e-05	CcSEcCtD
Mefloquine—Nausea—Dexamethasone—hematologic cancer	1.92e-05	8.19e-05	CcSEcCtD
Mefloquine—Nausea—Betamethasone—hematologic cancer	1.92e-05	8.19e-05	CcSEcCtD
Mefloquine—Decreased appetite—Epirubicin—hematologic cancer	1.91e-05	8.16e-05	CcSEcCtD
Mefloquine—Hypotension—Doxorubicin—hematologic cancer	1.9e-05	8.12e-05	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Epirubicin—hematologic cancer	1.9e-05	8.11e-05	CcSEcCtD
Mefloquine—Fatigue—Epirubicin—hematologic cancer	1.9e-05	8.09e-05	CcSEcCtD
Mefloquine—Urticaria—Methotrexate—hematologic cancer	1.87e-05	7.97e-05	CcSEcCtD
Mefloquine—Dizziness—Prednisone—hematologic cancer	1.86e-05	7.94e-05	CcSEcCtD
Mefloquine—Body temperature increased—Methotrexate—hematologic cancer	1.86e-05	7.93e-05	CcSEcCtD
Mefloquine—Abdominal pain—Methotrexate—hematologic cancer	1.86e-05	7.93e-05	CcSEcCtD
Mefloquine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	1.85e-05	7.91e-05	CcSEcCtD
Mefloquine—Insomnia—Doxorubicin—hematologic cancer	1.84e-05	7.86e-05	CcSEcCtD
Mefloquine—Paraesthesia—Doxorubicin—hematologic cancer	1.83e-05	7.8e-05	CcSEcCtD
Mefloquine—Dyspnoea—Doxorubicin—hematologic cancer	1.81e-05	7.74e-05	CcSEcCtD
Mefloquine—Feeling abnormal—Epirubicin—hematologic cancer	1.81e-05	7.74e-05	CcSEcCtD
Mefloquine—Somnolence—Doxorubicin—hematologic cancer	1.81e-05	7.72e-05	CcSEcCtD
Mefloquine—Gastrointestinal pain—Epirubicin—hematologic cancer	1.8e-05	7.68e-05	CcSEcCtD
Mefloquine—Dyspepsia—Doxorubicin—hematologic cancer	1.79e-05	7.65e-05	CcSEcCtD
Mefloquine—Vomiting—Prednisone—hematologic cancer	1.79e-05	7.63e-05	CcSEcCtD
Mefloquine—Rash—Prednisone—hematologic cancer	1.77e-05	7.57e-05	CcSEcCtD
Mefloquine—Dermatitis—Prednisone—hematologic cancer	1.77e-05	7.56e-05	CcSEcCtD
Mefloquine—Decreased appetite—Doxorubicin—hematologic cancer	1.77e-05	7.55e-05	CcSEcCtD
Mefloquine—Headache—Prednisone—hematologic cancer	1.76e-05	7.52e-05	CcSEcCtD
Mefloquine—Gastrointestinal disorder—Doxorubicin—hematologic cancer	1.76e-05	7.5e-05	CcSEcCtD
Mefloquine—Fatigue—Doxorubicin—hematologic cancer	1.75e-05	7.49e-05	CcSEcCtD
Mefloquine—Urticaria—Epirubicin—hematologic cancer	1.75e-05	7.46e-05	CcSEcCtD
Mefloquine—Body temperature increased—Epirubicin—hematologic cancer	1.74e-05	7.42e-05	CcSEcCtD
Mefloquine—Abdominal pain—Epirubicin—hematologic cancer	1.74e-05	7.42e-05	CcSEcCtD
Mefloquine—Hypersensitivity—Methotrexate—hematologic cancer	1.73e-05	7.39e-05	CcSEcCtD
Mefloquine—Asthenia—Methotrexate—hematologic cancer	1.69e-05	7.2e-05	CcSEcCtD
Mefloquine—Feeling abnormal—Doxorubicin—hematologic cancer	1.68e-05	7.16e-05	CcSEcCtD
Mefloquine—Nausea—Prednisone—hematologic cancer	1.67e-05	7.13e-05	CcSEcCtD
Mefloquine—Gastrointestinal pain—Doxorubicin—hematologic cancer	1.66e-05	7.1e-05	CcSEcCtD
Mefloquine—Pruritus—Methotrexate—hematologic cancer	1.66e-05	7.1e-05	CcSEcCtD
Mefloquine—Hypersensitivity—Epirubicin—hematologic cancer	1.62e-05	6.92e-05	CcSEcCtD
Mefloquine—Urticaria—Doxorubicin—hematologic cancer	1.62e-05	6.9e-05	CcSEcCtD
Mefloquine—Abdominal pain—Doxorubicin—hematologic cancer	1.61e-05	6.87e-05	CcSEcCtD
Mefloquine—Body temperature increased—Doxorubicin—hematologic cancer	1.61e-05	6.87e-05	CcSEcCtD
Mefloquine—Diarrhoea—Methotrexate—hematologic cancer	1.61e-05	6.86e-05	CcSEcCtD
Mefloquine—Asthenia—Epirubicin—hematologic cancer	1.58e-05	6.74e-05	CcSEcCtD
Mefloquine—Pruritus—Epirubicin—hematologic cancer	1.56e-05	6.64e-05	CcSEcCtD
Mefloquine—Dizziness—Methotrexate—hematologic cancer	1.55e-05	6.63e-05	CcSEcCtD
Mefloquine—Diarrhoea—Epirubicin—hematologic cancer	1.5e-05	6.42e-05	CcSEcCtD
Mefloquine—Hypersensitivity—Doxorubicin—hematologic cancer	1.5e-05	6.4e-05	CcSEcCtD
Mefloquine—Vomiting—Methotrexate—hematologic cancer	1.49e-05	6.38e-05	CcSEcCtD
Mefloquine—Rash—Methotrexate—hematologic cancer	1.48e-05	6.33e-05	CcSEcCtD
Mefloquine—Dermatitis—Methotrexate—hematologic cancer	1.48e-05	6.32e-05	CcSEcCtD
Mefloquine—Headache—Methotrexate—hematologic cancer	1.47e-05	6.28e-05	CcSEcCtD
Mefloquine—Asthenia—Doxorubicin—hematologic cancer	1.46e-05	6.23e-05	CcSEcCtD
Mefloquine—Dizziness—Epirubicin—hematologic cancer	1.45e-05	6.21e-05	CcSEcCtD
Mefloquine—Pruritus—Doxorubicin—hematologic cancer	1.44e-05	6.15e-05	CcSEcCtD
Mefloquine—Vomiting—Epirubicin—hematologic cancer	1.4e-05	5.97e-05	CcSEcCtD
Mefloquine—Nausea—Methotrexate—hematologic cancer	1.4e-05	5.96e-05	CcSEcCtD
Mefloquine—Diarrhoea—Doxorubicin—hematologic cancer	1.39e-05	5.94e-05	CcSEcCtD
Mefloquine—Rash—Epirubicin—hematologic cancer	1.39e-05	5.92e-05	CcSEcCtD
Mefloquine—Dermatitis—Epirubicin—hematologic cancer	1.39e-05	5.91e-05	CcSEcCtD
Mefloquine—Headache—Epirubicin—hematologic cancer	1.38e-05	5.88e-05	CcSEcCtD
Mefloquine—Dizziness—Doxorubicin—hematologic cancer	1.35e-05	5.74e-05	CcSEcCtD
Mefloquine—Nausea—Epirubicin—hematologic cancer	1.31e-05	5.58e-05	CcSEcCtD
Mefloquine—Vomiting—Doxorubicin—hematologic cancer	1.29e-05	5.52e-05	CcSEcCtD
Mefloquine—Rash—Doxorubicin—hematologic cancer	1.28e-05	5.48e-05	CcSEcCtD
Mefloquine—Dermatitis—Doxorubicin—hematologic cancer	1.28e-05	5.47e-05	CcSEcCtD
Mefloquine—Headache—Doxorubicin—hematologic cancer	1.27e-05	5.44e-05	CcSEcCtD
Mefloquine—Nausea—Doxorubicin—hematologic cancer	1.21e-05	5.16e-05	CcSEcCtD
Mefloquine—ABCB1—Metabolism—GSTO1—hematologic cancer	6.17e-06	5.46e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TSC2—hematologic cancer	6.16e-06	5.45e-05	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—PIK3CA—hematologic cancer	6.14e-06	5.43e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PC—hematologic cancer	6.11e-06	5.4e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—KRAS—hematologic cancer	6.07e-06	5.37e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SPHK1—hematologic cancer	6.04e-06	5.34e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—FGF2—hematologic cancer	5.93e-06	5.25e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FGFR3—hematologic cancer	5.93e-06	5.25e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC35B2—hematologic cancer	5.9e-06	5.22e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GBA—hematologic cancer	5.9e-06	5.22e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—IDH1—hematologic cancer	5.88e-06	5.2e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK14—hematologic cancer	5.87e-06	5.19e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3R1—hematologic cancer	5.85e-06	5.18e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTO1—hematologic cancer	5.82e-06	5.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCC3—hematologic cancer	5.82e-06	5.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—TXN—hematologic cancer	5.82e-06	5.14e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—UGT1A1—hematologic cancer	5.8e-06	5.13e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—ESR1—hematologic cancer	5.76e-06	5.09e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SPHK1—hematologic cancer	5.69e-06	5.03e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JAK2—hematologic cancer	5.69e-06	5.03e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FN1—hematologic cancer	5.69e-06	5.03e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—MTHFR—hematologic cancer	5.69e-06	5.03e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—hematologic cancer	5.68e-06	5.03e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CRABP1—hematologic cancer	5.64e-06	4.99e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SLC22A1—hematologic cancer	5.64e-06	4.99e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—BAD—hematologic cancer	5.62e-06	4.97e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NFKBIA—hematologic cancer	5.62e-06	4.97e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—PIK3CA—hematologic cancer	5.57e-06	4.93e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NOTCH1—hematologic cancer	5.57e-06	4.92e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MDM2—hematologic cancer	5.55e-06	4.91e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—MTHFR—hematologic cancer	5.52e-06	4.88e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALOX5—hematologic cancer	5.5e-06	4.87e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—hematologic cancer	5.5e-06	4.87e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—UGT1A1—hematologic cancer	5.47e-06	4.84e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.45e-06	4.82e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CD80—hematologic cancer	5.45e-06	4.82e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KIT—hematologic cancer	5.44e-06	4.82e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CG—hematologic cancer	5.44e-06	4.82e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—NRAS—hematologic cancer	5.44e-06	4.82e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MTOR—hematologic cancer	5.4e-06	4.78e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CB—hematologic cancer	5.4e-06	4.78e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTAP—hematologic cancer	5.4e-06	4.77e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTPN11—hematologic cancer	5.35e-06	4.73e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NUP98—hematologic cancer	5.33e-06	4.71e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SLC22A1—hematologic cancer	5.32e-06	4.71e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CRABP1—hematologic cancer	5.32e-06	4.71e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—MAPK3—hematologic cancer	5.21e-06	4.61e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CG—hematologic cancer	5.2e-06	4.6e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALOX5—hematologic cancer	5.18e-06	4.59e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CREB1—hematologic cancer	5.18e-06	4.58e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOA3—hematologic cancer	5.17e-06	4.58e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ADCY7—hematologic cancer	5.17e-06	4.58e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—HRAS—hematologic cancer	5.16e-06	4.56e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NUP214—hematologic cancer	5.14e-06	4.54e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—BRAF—hematologic cancer	5.12e-06	4.53e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCL2—hematologic cancer	5.07e-06	4.49e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1B—hematologic cancer	5.07e-06	4.49e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6R—hematologic cancer	5.05e-06	4.47e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CREBBP—hematologic cancer	5.05e-06	4.46e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ABCG2—hematologic cancer	5.03e-06	4.45e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MTR—hematologic cancer	5.03e-06	4.45e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NUP98—hematologic cancer	5.02e-06	4.44e-05	CbGpPWpGaD
Mefloquine—ADORA1—GPCR downstream signaling—AKT1—hematologic cancer	5.01e-06	4.44e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.01e-06	4.43e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CASP3—hematologic cancer	4.97e-06	4.4e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL2—hematologic cancer	4.96e-06	4.39e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—IL6—hematologic cancer	4.94e-06	4.37e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ENO2—hematologic cancer	4.93e-06	4.36e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ADCY7—hematologic cancer	4.87e-06	4.31e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOA3—hematologic cancer	4.87e-06	4.31e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	4.87e-06	4.3e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NUP214—hematologic cancer	4.84e-06	4.28e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CCND1—hematologic cancer	4.84e-06	4.28e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—JUN—hematologic cancer	4.83e-06	4.27e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—CREBBP—hematologic cancer	4.82e-06	4.26e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAP2K1—hematologic cancer	4.82e-06	4.26e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—FHL2—hematologic cancer	4.81e-06	4.26e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CD—hematologic cancer	4.79e-06	4.23e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTT1—hematologic cancer	4.79e-06	4.23e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CG—hematologic cancer	4.78e-06	4.23e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCG2—hematologic cancer	4.74e-06	4.19e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTR—hematologic cancer	4.74e-06	4.19e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—PIK3CA—hematologic cancer	4.74e-06	4.19e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AGRN—hematologic cancer	4.72e-06	4.17e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—KRAS—hematologic cancer	4.68e-06	4.14e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—CDKN1A—hematologic cancer	4.68e-06	4.14e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—SDC1—hematologic cancer	4.68e-06	4.14e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PTEN—hematologic cancer	4.67e-06	4.13e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ENO2—hematologic cancer	4.65e-06	4.11e-05	CbGpPWpGaD
Mefloquine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—hematologic cancer	4.64e-06	4.11e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CG—hematologic cancer	4.64e-06	4.1e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—FGF2—hematologic cancer	4.58e-06	4.05e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CD—hematologic cancer	4.57e-06	4.04e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK8—hematologic cancer	4.57e-06	4.04e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling by GPCR—AKT1—hematologic cancer	4.55e-06	4.03e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3R1—hematologic cancer	4.52e-06	4e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—ALB—hematologic cancer	4.51e-06	3.99e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTT1—hematologic cancer	4.51e-06	3.99e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	4.48e-06	3.96e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—IDH2—hematologic cancer	4.47e-06	3.96e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HMMR—hematologic cancer	4.47e-06	3.96e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—EP300—hematologic cancer	4.45e-06	3.94e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—CREBBP—hematologic cancer	4.43e-06	3.92e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—SDC1—hematologic cancer	4.41e-06	3.9e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JAK2—hematologic cancer	4.39e-06	3.89e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—SRC—hematologic cancer	4.33e-06	3.83e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3R1—hematologic cancer	4.32e-06	3.82e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—PIK3CA—hematologic cancer	4.3e-06	3.81e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—CREBBP—hematologic cancer	4.3e-06	3.8e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MDM2—hematologic cancer	4.29e-06	3.79e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—VEGFA—hematologic cancer	4.22e-06	3.73e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ARNTL—hematologic cancer	4.2e-06	3.72e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CD—hematologic cancer	4.2e-06	3.72e-05	CbGpPWpGaD
Mefloquine—ABCB1—Transmembrane transport of small molecules—ALB—hematologic cancer	4.19e-06	3.71e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—STAT3—hematologic cancer	4.17e-06	3.69e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CB—hematologic cancer	4.17e-06	3.69e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MTOR—hematologic cancer	4.17e-06	3.69e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—NRAS—hematologic cancer	4.16e-06	3.68e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—ALB—hematologic cancer	4.15e-06	3.67e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ACP5—hematologic cancer	4.09e-06	3.62e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CA9—hematologic cancer	4.09e-06	3.62e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CD—hematologic cancer	4.08e-06	3.61e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOR2—hematologic cancer	4.04e-06	3.57e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—ALB—hematologic cancer	4.03e-06	3.56e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MAPK3—hematologic cancer	3.99e-06	3.53e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CB—hematologic cancer	3.98e-06	3.52e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—HRAS—hematologic cancer	3.98e-06	3.52e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NQO1—hematologic cancer	3.98e-06	3.52e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CD44—hematologic cancer	3.98e-06	3.52e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3R1—hematologic cancer	3.97e-06	3.51e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1B—hematologic cancer	3.91e-06	3.46e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—MYC—hematologic cancer	3.88e-06	3.43e-05	CbGpPWpGaD
Mefloquine—ADORA2A—GPCR downstream signaling—AKT1—hematologic cancer	3.87e-06	3.43e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TGFB1—hematologic cancer	3.87e-06	3.42e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3R1—hematologic cancer	3.85e-06	3.41e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—IDH1—hematologic cancer	3.85e-06	3.4e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CASP3—hematologic cancer	3.84e-06	3.39e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL2—hematologic cancer	3.83e-06	3.39e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—IL6—hematologic cancer	3.81e-06	3.37e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTO1—hematologic cancer	3.8e-06	3.36e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—TXN—hematologic cancer	3.8e-06	3.36e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCC3—hematologic cancer	3.8e-06	3.36e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CYCS—hematologic cancer	3.76e-06	3.33e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CD44—hematologic cancer	3.75e-06	3.32e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NQO1—hematologic cancer	3.75e-06	3.32e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—HSP90AA1—hematologic cancer	3.74e-06	3.31e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CCND1—hematologic cancer	3.73e-06	3.3e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—JUN—hematologic cancer	3.73e-06	3.3e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SPHK1—hematologic cancer	3.72e-06	3.29e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CB—hematologic cancer	3.66e-06	3.24e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—CDKN1A—hematologic cancer	3.61e-06	3.2e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PTEN—hematologic cancer	3.6e-06	3.19e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—KRAS—hematologic cancer	3.58e-06	3.17e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—UGT1A1—hematologic cancer	3.57e-06	3.16e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CB—hematologic cancer	3.55e-06	3.14e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CYCS—hematologic cancer	3.55e-06	3.14e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK8—hematologic cancer	3.53e-06	3.12e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—HSP90AA1—hematologic cancer	3.52e-06	3.12e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling by GPCR—AKT1—hematologic cancer	3.52e-06	3.11e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SLC22A1—hematologic cancer	3.48e-06	3.08e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CRABP1—hematologic cancer	3.48e-06	3.08e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PTEN—hematologic cancer	3.44e-06	3.05e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—EP300—hematologic cancer	3.44e-06	3.04e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALOX5—hematologic cancer	3.39e-06	3e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—SRC—hematologic cancer	3.34e-06	2.96e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTP1—hematologic cancer	3.32e-06	2.93e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—PIK3CA—hematologic cancer	3.29e-06	2.91e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—EP300—hematologic cancer	3.28e-06	2.9e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NUP98—hematologic cancer	3.28e-06	2.9e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—VEGFA—hematologic cancer	3.26e-06	2.88e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—STAT3—hematologic cancer	3.22e-06	2.85e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—NRAS—hematologic cancer	3.22e-06	2.84e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ADCY7—hematologic cancer	3.19e-06	2.82e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOA3—hematologic cancer	3.19e-06	2.82e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—TP53—hematologic cancer	3.19e-06	2.82e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NUP214—hematologic cancer	3.16e-06	2.8e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PTEN—hematologic cancer	3.16e-06	2.8e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTP1—hematologic cancer	3.13e-06	2.77e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTR—hematologic cancer	3.1e-06	2.74e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCG2—hematologic cancer	3.1e-06	2.74e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MAPK3—hematologic cancer	3.08e-06	2.72e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PTEN—hematologic cancer	3.07e-06	2.72e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—NCOR1—hematologic cancer	3.05e-06	2.7e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—GSTM1—hematologic cancer	3.05e-06	2.7e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—HRAS—hematologic cancer	3.05e-06	2.7e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ENO2—hematologic cancer	3.04e-06	2.69e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—EP300—hematologic cancer	3.02e-06	2.67e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—MYC—hematologic cancer	3e-06	2.65e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TGFB1—hematologic cancer	2.99e-06	2.64e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ABCB1—hematologic cancer	2.96e-06	2.62e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTT1—hematologic cancer	2.95e-06	2.61e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—EP300—hematologic cancer	2.93e-06	2.59e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—IL6—hematologic cancer	2.92e-06	2.58e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—SDC1—hematologic cancer	2.88e-06	2.55e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—NCOR1—hematologic cancer	2.87e-06	2.54e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—GSTM1—hematologic cancer	2.87e-06	2.54e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—KRAS—hematologic cancer	2.77e-06	2.45e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—MTHFR—hematologic cancer	2.69e-06	2.38e-05	CbGpPWpGaD
Mefloquine—ADORA1—Signaling Pathways—AKT1—hematologic cancer	2.69e-06	2.38e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—PIK3CA—hematologic cancer	2.54e-06	2.25e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—MTHFR—hematologic cancer	2.54e-06	2.25e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—TP53—hematologic cancer	2.46e-06	2.18e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NQO1—hematologic cancer	2.45e-06	2.17e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CD44—hematologic cancer	2.45e-06	2.17e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—PIK3CA—hematologic cancer	2.43e-06	2.15e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—HRAS—hematologic cancer	2.35e-06	2.08e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CYCS—hematologic cancer	2.32e-06	2.05e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—HSP90AA1—hematologic cancer	2.3e-06	2.04e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CG—hematologic cancer	2.26e-06	2e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—IL6—hematologic cancer	2.25e-06	1.99e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—PIK3CA—hematologic cancer	2.23e-06	1.97e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—PIK3CA—hematologic cancer	2.17e-06	1.92e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CG—hematologic cancer	2.13e-06	1.89e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—CREBBP—hematologic cancer	2.1e-06	1.86e-05	CbGpPWpGaD
Mefloquine—ADORA2A—Signaling Pathways—AKT1—hematologic cancer	2.08e-06	1.84e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTP1—hematologic cancer	2.04e-06	1.81e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CD—hematologic cancer	1.99e-06	1.76e-05	CbGpPWpGaD
Mefloquine—ACHE—Metabolism—AKT1—hematologic cancer	1.98e-06	1.76e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—CREBBP—hematologic cancer	1.98e-06	1.75e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—ALB—hematologic cancer	1.96e-06	1.74e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ABCB1—hematologic cancer	1.93e-06	1.71e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3R1—hematologic cancer	1.88e-06	1.66e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—GSTM1—hematologic cancer	1.88e-06	1.66e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—NCOR1—hematologic cancer	1.88e-06	1.66e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CD—hematologic cancer	1.87e-06	1.66e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—ALB—hematologic cancer	1.85e-06	1.64e-05	CbGpPWpGaD
Mefloquine—CYP19A1—Metabolism—AKT1—hematologic cancer	1.82e-06	1.61e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3R1—hematologic cancer	1.77e-06	1.57e-05	CbGpPWpGaD
Mefloquine—BCHE—Metabolism—AKT1—hematologic cancer	1.77e-06	1.57e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CB—hematologic cancer	1.73e-06	1.53e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—MTHFR—hematologic cancer	1.66e-06	1.47e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CB—hematologic cancer	1.63e-06	1.45e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PTEN—hematologic cancer	1.5e-06	1.33e-05	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—EP300—hematologic cancer	1.43e-06	1.26e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PTEN—hematologic cancer	1.41e-06	1.25e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CG—hematologic cancer	1.39e-06	1.23e-05	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—EP300—hematologic cancer	1.35e-06	1.19e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—CREBBP—hematologic cancer	1.29e-06	1.14e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CD—hematologic cancer	1.23e-06	1.08e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—ALB—hematologic cancer	1.21e-06	1.07e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3R1—hematologic cancer	1.16e-06	1.02e-05	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CB—hematologic cancer	1.07e-06	9.45e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—PIK3CA—hematologic cancer	1.06e-06	9.35e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—PIK3CA—hematologic cancer	9.96e-07	8.81e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PTEN—hematologic cancer	9.23e-07	8.17e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—EP300—hematologic cancer	8.8e-07	7.79e-06	CbGpPWpGaD
Mefloquine—ABCB1—Metabolism—AKT1—hematologic cancer	8.64e-07	7.64e-06	CbGpPWpGaD
Mefloquine—CYP2D6—Metabolism—AKT1—hematologic cancer	8.14e-07	7.2e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—PIK3CA—hematologic cancer	6.51e-07	5.76e-06	CbGpPWpGaD
Mefloquine—CYP3A4—Metabolism—AKT1—hematologic cancer	5.32e-07	4.71e-06	CbGpPWpGaD
